FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes
23/12/2024
Leggi
AIFA: Attivazione web e pubblicazione schede di monitoraggio – PT web «Vazkepa» (icosapent etile)
16/12/2024
Leggi
AIFA: Riclassificazione del medicinale per uso umano «Vazkepa» (icosapent etile) in classe A (GU Serie Generale n.293 del 14-12-2024)
16/12/2024
Leggi
Automated insulin delivery in older adults with type 1 diabetes
Kudva YC, Henderson RJ, Kanapka LG, et al.
NEJM Evid. 2025;4(1):EVIDoa2400200.
Leggi
The effect of automated insulin delivery system use on diabetes distress in people with type 1 diabetes and their caregivers: A systematic review and meta-analysis
Canha D, McMahon V, Schmitz S, et al.
Diabet Med. 2024:e15503.
Leggi
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes
Shapiro MR, Tallon EM, Brown ME, et al.
Diabetologia. Pub. online 19 Dec 2024.
Leggi
Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis
Teng Y, Fan X, Yu R, Yang X
BMC Endocr Disord. 2024;24(1):278.
Leggi
Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes
Snell-Bergeon JK, Kaur G, Renner D, et al.
Diabetes Technol Ther. Pub. online 2 Jan 2025.
Leggi
Predicting responsiveness to GLP-1 pathway drugs using real-world data
Zhu X, Fowler MJ, Wells QS, et al.
BMC Endocr Disord. 2024;24(1):269.
Leggi
Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study
Karges B, Rosenbauer J, Stahl-Pehe A, et al.
Lancet Diabetes Endocrinol. 2024:S2213-8587(24)00284-5.
Leggi